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Since the ﬁrst cord blood transplantation in 1988, umbilical cord blood has become an important option as a
source of cells for hematopoietic transplantation. Beyond its role in regenerating the blood and immune
systems to treat blood diseases and inherited metabolic disorders, the role of nonhematopoietic progenitor
cells in cord blood has led to new and emerging uses of umbilical cord blood in regenerative therapy and
immune modulation. In this review, we provide an update on the clinical and preclinical studies using cord
bloodederived cells such as mesenchymal stromal cells, endothelial-like progenitor cells, and others. We also
provide insight on the use of cord blood cells as vehicles for the delivery of therapeutic agents through gene
therapy and microvesicle-associated strategies. Moreover, cord blood can provide essential reagents for
regenerative applications. Clinical activity using cord blood cells is increasing rapidly and this review aims to
provide an important update on the tremendous potential within this fast-moving ﬁeld.
 2015 American Society for Blood and Marrow Transplantation.INTRODUCTION
Widespread use of human umbilical cord blood (UCB) as a
source of hematopoietic stem and progenitor cells for
transplantation in patients undergoing treatment for leuke-
mia, other blood disorders, and inherited metabolic diseases
has been complemented more recently by the promise of
regenerative therapy using nonhematopoietic cells present
in cord blood [1]. Major nonhematopoietic cell types that can
be readily expanded ex vivo using established methods
include mesenchymal stromal cells (MSCs) and endothelial-
like vascular progenitors (EPCs) that will be reviewed in
greater detail. Moreover, technical hurdles to overcome
before more widespread clinical use is realized are discussed
and indirect uses of UCB-derived cells are presented to
illustrate the broad scope of potential applications in
regenerative therapy using umbilical cord blood.MSCs
MSCs comprise a rare population of multipotent peri-
vascular progenitors capable of supporting hematopoiesis indgments on page 1552.
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ty for Blood and Marrow Transplantation.bone marrow (BM) niches, differentiating into multiple
mesenchymal lineages, such as osteogenic, adipogenic, and
chondrogenic cells, and possess immune modulatory prop-
erties that may be applicable in the treatment of inﬂamma-
tory or autoimmune conditions [2]. MSCs can be derived
from various adult organs including adipose tissue [3],
BM [2] or UCB, and placental tissues [4,5]. Indeed, MSCs
have been used increasingly in clinical trials with the
recent development of consensus deﬁnitions [6] and the
use of standard functional assays that meet regulatory
requirements. Moreover, national blood operators in some
jurisdictions have embraced manufacturing of MSCs for
human use [7,8] and an increasing number of academic
institutions and private companies are investing in cell
manufacturing facilities to accommodate MSC-based clinical
applications.
Although most studies use marrow-derived MSCs, the
derivation of MSCs from UCB was ﬁrst identiﬁed in the early
2000s [4,9], but they could only be expanded from aminority
of samples [10]. Sharing morphological and phenotypic
similarities with BM-derived MSCs, UCB-derived MSCs
display a predominantly plastic-adherent ﬁbroblast-like
morphology in vitro with an immunophenotype that in-
cludes surface expression of CD73, CD90, and CD105 as well
as more recently recognized markers CD44, CD146, and
CD166 that may allow further enrichment of cells within
Figure 1. UCB-derived cells beyond hematopoietic progenitors and current applications in regenerative medicine.
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are distinct from hematopoietic cells and lack surface
expression of typical hematopoietic markers including CD3,
CD14, CD31, CD34, CD45, CD144, vascular endothelial growth
factor (VEGF)-R1, and VEGF-R2. In some reports, UCB-
derived MSCs can be distinguished from BM-derived MSCs
by the surface expression of intercellular adhesion molecule
1 (ICAM-1), also known as CD54, which is expressed at
higher levels on UCB-derived MSCs than it is on BM-derived
MSCs [2,11]. The biological importance of increased ICAM-1
surface expression remains under active study. UCB-
derived MSCs, however, retain multilineage differentiation
potential towards osteogenic, adipogenic, and chondrogenic
lineages [11-13]. Moreover, UCB-derived MSCs can be
induced towards typical neuron-like morphology (long bi-
polar extensions and branching ends) when cultured in a
neuron-inducing medium [14]. Differentiation into neural
cells can be conﬁrmed by expression of cytoskeletal proteins
found in neurons and astrocytes like betubulin III and glial
ﬁbrillary acidic protein [12].
UCB-derived MSCs can also differentiate towards
hepatocyte-like cells, acquiring a hepatocyte gene expression
proﬁle, including increased expression of albumin, alpha
fetoprotein (AFP), cytokeratin (CK)-18, glutamine synthetase,
and tyrosine aminotransferase. In addition, the newly formed
hepatocyte-like cells display functional low-density lipopro-
tein incorporation capability [15]. Additional studies have
reported muscle cell generation from UCB-derived MSCs,
which remains under active investigation [16]. Skeletalmyogenic differentiation can be demonstrated by mRNA
expression ofMyoD andmyogenin, 2 important transcription
factors in myogenic differentiation [17]. Differentiation of
MSCs into functional cardiomyocytes with expression of N-
cadherin and cardiac troponin has been inconsistent. In
particular, UCB-derivedMSCs may have broader applicability
in regenerative therapy thanMSCs derived fromadult tissues,
such as marrow or adipose tissue, because of the loss of
differentiating potential that is associated with aging [9].
Taken together, UCB-derived MSCs represent a promising
candidate for stem cellebased regenerative therapy for a
broad range of damaged tissues (Figure 1).
Although MSCs from cord blood appear promising, MSCs
can also be derived from other cord blood itself, the placenta,
and other tissues, including bone, muscles, and adipose tis-
sue. Although direct comparisons between different tissues
sources have not been studied extensively, it is likely that
MSCs derived from different tissues may have particular
advantages in speciﬁc indications. Compared with UCB- and
BM-derived MSCs, adipose tissueederived MSCs did not
prevent glioblastoma cell growth in 1 study [18], whereas
adipose tissueederived MSCs are promising candidates for
inhibiting melanoma cell growth [19]. Moreover, muscle-
derived MSCs appear particularly potent in the modulation
of myoblast proliferation, supporting the use of tissue-
speciﬁc MSCs for particular applications [20].
It has proven more difﬁcult to expand MSCs from UCB
than it is with marrow-derived MSCs, with an estimated
frequency of only 1000 to 5000 MSCs in a typical UCB unit of
Table 1
Registered Clinical Trials Using UCB Cells as Regenerative Therapy or Immune Modulation: An Update from Iafolla et al. [28]
Clinical Area Targeted Disorder UCB-Derived
Cell Type Used
in the Trial
Source of Cord Blood Cells Route of UCB Cells
Administration
Total
Mononuclear
Cells
MSC Autologous Allogeneic Not
Speciﬁed
Intravenous Directly in
Injured
Organ
Not
Speciﬁed
Cardiovascular
diseases*
(4 studies)
Hypoplastic left heart
syndrome, ischemic
cardiomyopathy, idiopathic
dilated cardiomyopathy
2 2 2 1 1 0 4 0
Neurodegenerative
disordersy
(19 studies)
Cerebral palsy and paralysis,
global developmental delay,
neonatal encephalopathy
6 2 2 4 2 2 1 5
Acquired brain injury, ischemic
stroke and encephalopathy,
critical limb ischemia
5 1 1 4 1 1 1 4
Injured spinal cord 1 0 0 1 0 0 1 0
Autism spectrum disorder 2 0 2 0 0 1 0 1
Alzheimer disease 0 2 0 2 0 1 1 0
Metabolic
disordersz
(18 studies)
Errors of metabolism-
congenital/inherited
7 0 0 3 4 1 0 6
Epidermolysis bullosa,
mucopolysaccharidosis
4 0 0 0 4 0 0 4
Diabetes: type 1 and type 2,
diabetic foot ulcers
0 5 0 3 2 3 1 1
Liver cirrhosis, ischemic-type
biliary lesion
1 1 0 1 1 1 0 1
Immunologic
disordersx
(7 studies)
Acquired hearing loss 2 1 2 1 0 3 0 0
Bronchopulmonary dysplasia 0 2 0 2 0 0 2 0
Systemic lupus erythematosus 1 0 0 1 0 1 0 0
Steroid-refractory acute or
chronic GVHD
0 1 0 1 0 1 0 0
Bone disordersk
(6 studies)
Osteopetrosis, articular
cartilage defects and injury
3 3 0 5 1 0 3 3
Other disorders{
(2 studies)
Ovarian failure 0 1 0 1 0 0 0 1
Solid malignant tumors 0 1 0 1 0 0 0 1
GVHD indicates graft-versus-host disease.
Data presented are the number of studies.
A total of 57 trials were identiﬁed from a total of 606 trials involving human umbilical cord blood transplantation, as of November 1, 2014.
Database source: ClinicalTrials.org registry.
* NCT01883076, NCT01445041, NCT01946048, NCT01219452.
y NCT01639404, NCT01486732, NCT02025972, NCT01988584, NCT01991145, NCT01885663, NCT00375908, NCT02236065, NCT01929434, NCT01769716,
NCT02176317, NCT01638819, NCT02054208, NCT01471613, NCT02256618, NCT01019681, NCT01962233, NCT01884155, NCT01297218.
z NCT00950846, NCT00950846, NCT00668564, NCT00176904, NCT00920972, NCT00654433, NCT00383448, NCT00881556, NCT00478244, NCT01238328,
NCT00176917, NCT01350219, NCT01954147, NCT02138331, NCT01216865, NCT01415726, NCT01942915, NCT0222389.
x NCT01343394, NCT01673789, NCT02038972, NCT01297205, NCT01897987, NCT00684255, NCT01549665.
k NCT00775931, NCT00638820, NCT01087398, NCT01733186, NCT01041001, NCT01626677.
{ NCT01742533, NCT0043676.
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production of clinical grade MSCs from cord blood or from
placental tissues has been accomplished by private and
public cell manufacturing facilities [22]. Beyond technical
limitations in UCB-derived MSC expansion, considerable
preclinical research activity has occurred using UCB-derived
MSCs to facilitate tissue repair in animal studies.
Rodent models of cardiovascular disease, peripheral
vascular disease, and neurological injury have been studied
extensively and appear promising in terms of improved
functional recovery after UCB-derived MSCs transplantation
[2]. The route of administration remains variable in these
studies and has not been optimized for all types of tissue
damage. For example, efﬁcacy in cardiac repair was ﬁrst
observed after direct myocardial injection, whereas infusion
through a central venous catheter or intracoronary infusion
may be more clinically relevant but has been less studied.
Moreover, local delivery of MSCs can be more challenging
in particular sites such as the central nervous system.
UCB-derived MSCs have also demonstrated promise inxenogeneic mouse models of liver injury [23] and islet
regeneration in type 1 diabetes [24]. Preclinical studies in a
rabbit model of intervertebral disc degeneration showed
improvement using UCB-derived MSCs that could differen-
tiate into chondrocyte-like cells [25]. Another study using
larger animal models addressed the use of equine
UCB-derived MSCs for immune modulation in horses [26].
The possibility that MSC-derived effects may be con-
tained in extracellular microvesicles such as exosomes that
are released from MSCs, and can integrate in target cells to
reprogram of modify gene expression patterns was recently
summarized in a systematic review [27]. Although signiﬁ-
cant publication bias is suspected, it appears that MSC-
derived exosomes may have therapeutic beneﬁt in tissue
repair and/or immune modulation and may be another
option to consider regarding the manufacturing of MSC-
derived cellular products.
The number of patients treated in clinical trials using
UCB-derived MSCs continues to increase. A recent systematic
review published by Iafolla et al. summarizes the use of cord
Table 2
Ongoing clinical trials in regenerative medicine ﬁeld using MSCs from diverse umbilical cord tissues.
Wharton’s Jelly-Derived MSCs, n Placenta-Derived MSCs, n Cord BloodeDerived MSCs, n
Cardiovascular diseases 2
NCT02368587 Ischemic
cardiomyopathy
NCT01291329 Acute myocardial
infarction
0 2
NCT01946048 Ischemic
Cardiomyopathy
NCT01219452 Idiopathic Dilated
Cardiomyopathy
Neurodegenerative disorders 0 0 5
NCT01929434 Cerebral Paralysis
NCT02054208 Alzheimer’s Disease
NCT01962233 Ischemic
Encephalopathy
NCT01297218 Alzheimer’s Disease
NCT01884155 Stroke
Metabolic disorders 0 1
NCT01413035 Type 2 diabetes
6
NCT01350219 Type 1 diabetes
NCT01954147 Type 1 diabetes
NCT02138331 Type 1 diabetes
NCT01216865 Diabetic foot
NCT01415726 Type 2 diabetes
NCT02223897 Ischemic-type biliary
lesions
Immunologic disorders 0 1
NCT00749164 GVHD
immunomudulation
4
NCT01673789 Alopecia areata
NCT01297205 Bronchopulmonary
dysplasia
NCT01897987 Bronchopulmonary
dysplasia
NCT01549665 Steroid-refractory
acute or chronic GVHD
Bone disorders 1
NCT01166776 Avascular necrosis
1
NCT01420432 Ankylosing
spondylitis
3
NCT01733186 Articular cartilage
defects
NCT01041001 Knee articular
cartilage injury
NCT01626677 Knee articular
cartilage injury
Other disorders 0 4
NCT01385644 Pulmonary ﬁbrosis
NCT02395029 Peyronie’s disease
NCT02398370 Erectile dysfunction
NCT01649752 ICSI rate
improvement
2
NCT01742533 Premature ovarian
failure
NCT00436761 Refractory or
relapsed malignant solid tumors
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erative therapy and immune modulation [28]. The main in-
dications for treating patients with cord bloodederived
MSCs in these studies were cardiovascular disease, neuro-
degenerative disorders, and metabolic or immunologic dis-
orders. In addition to published studies, ongoing registered
clinical studies were also systematically summarized to
provide an indication of the trend regarding new indications
that may be expected in the near future. Table 1 provides a
more recent update since Iafolla et al. [28] published the
systematic review and attests that the use of UCB cells in
human trials is increasing. From the number of registered
trials, we should expect increasing activity using cord
bloodederived MSCs to treat patients with neurological
disorders and for immune modulation. Although some
studies use MSCs expanded from UCB, many trials infuse
unmanipulated or minimally manipulated total mono-
nuclear cells from UCB units, making it more difﬁcult to
know which cell type is most responsible for the clinical
beneﬁt in these emerging indications. It will be difﬁcult to
conclude that MSCs are responsible for beneﬁts observed in
these patients and iterative improvements in the cell-based
therapy strategies may be difﬁcult unless cellular products
are well characterized.Despite the rapid growth in clinical studies of cord
bloodederived stem and progenitor cells for an expanding
list of new indications, surprisingly little is known about the
mechanisms of cell-mediated tissue repair or immune
modulation. In vivo monitoring of cell engraftment and
survival has been used to gain greater insight regarding the
capacity of cells to home and engraft in areas of tissue
damage. The most popular technique to track UCB-derived
MSCs in preclinical animal studies is based on the green
ﬂuorescent protein reporter gene transfection. After sacri-
ﬁcing treated animals and assessing injured tissues, such as
the brain, using microscopic analysis, green ﬂuorescent
protein signals demonstrate that UCB stem cells can home to
the injured brain [29]. In recipients of UCB transplantation,
donor cells in the brain have been described at autopsy in
patients with Hunter disease [30]. Live tracking in animals
has recently emerged as a new and powerful approach to
seeing how transplanted cells home to areas of tissue dam-
age but has not yet been reported in patients. In 1 example,
cord bloodederived progenitors were transduced with a
retroviral symporter system and combined with positron
emission tomography and magnetic resonance imaging to
identify transplanted cells in the injured myocardium on day
7 after myocardial transplantation [31].
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key element of successful cell-based therapy. Building on
knowledge of how hematopoietic progenitors home to BM
via CXCR4-SDF-1 interactions and the PI3K/Akt pathway,
many groups have provided insight on MSC homing to areas
of ischemic tissue injury [32]. Indeed, MSCs appear to sense
hypoxia and can migrate to areas of ischemia, thereby
focusing chemoattractant gradients in the areas of damage
[33]. Human MSCs mRNA expression and ﬂow cytometry
analysis have identiﬁed several cytokines/chemokine re-
ceptors that could be involved in MSC homing, including
CCR1, CCR2, CCR4, CCR7, CCR9, as well as CXCR5 and CXCR6
[34,35]. All of these receptors respond to their cognate ligand
by inducing human MSC migration in chemotactic transwell
chambers. Trafﬁcking of MSCs may also be inﬂuenced by
molecules other than CC or CXC receptor ligands. Sackstein
et al. demonstrated that MSCs use CD44 and that MSC
homing can be improved by modifying the glycosylation
pattern on CD44 [36]. This capacity to modulate homing of
MSCs and to increase their homing function or ability to
target speciﬁc tissues may prove very useful for future clin-
ical applications. Moreover, the observation that infused
MSCs may get trapped in the lung and induce favorable local
repair responses [37] reopens the debate regarding direct
injection of MSCs into injured organs. When MSCs or other
speciﬁc progenitors localize in injured tissues, trans-
migration mechanisms from the bloodstream into the tissue
appears critical but remains poorly understood. Both passive
migration into tissues and active mechanisms similar to
leukocyte transmigration have been described and strategies
to enhance this process represent promising future strategies
to enhance cell-based regenerative therapy. Phenomena
such as transdifferentiation of MSCs and other progenitor
cells to new cell types have been described in vitro, along
with the observation that transplanted cells can fuse with
resident cells in the injured tissue, such as the liver [21,38].
However, therapeutic beneﬁt can also be observed without
any signiﬁcant functional engraftment of transplanted MSCs,
suggesting the paracrine function of MSCs is central to their
therapeutic effects.
It is important to acknowledge that most studies and
ongoing human trials using umbilical cordederived MSCs
have used UCB itself rather than placental tissues or cord-
related tissue. In parallel, an increasing number of studies
describe the isolation and characterization of MSCs from
placental tissue [39] or Wharton’s jelly [40], with more
robust and rapid expansion of cells. Some ongoing clinical
trials also describe the use of umbilical cord matrixederived
MSCs (see Table 2). It remains premature to compare in vivo
studies of tissue regeneration using MSCs derived from UCB
compared with from other sources.
Cord bloodederived MSCs appear poised for increased
clinical studies in the near future with many preclinical and
clinical studies supporting their use. We anticipate ongoing
reﬁnement in cell manufacturing that will facilitate more
widespread application of these promising strategies. Gov-
ernments, health authorities, and blood establishments
should prepare for increasing presence of cord blood
MSCebased therapies in the near future.
ENDOTHELIAL-LIKE VASCULAR PROGENITOR CELLS
A number of cells with angiogenic capacity, collectively
termed endothelial-like vascular progenitors, have been
studied extensively in recent years and have the capacity to
facilitate repair after vascular injury in animal models ofmyocardial injury, cerebrovascular damage, kidney injury,
and other types of organ damage. Endothelial progenitor
cells (EPCs) were ﬁrst described in 1997 by Asahara et al. by
isolating a subset of CD34-selected cells from BM that
coexpressed surface marker CD133 and the endothelial
lineage marker, KDR (VEGFR-2) [41]. Absence of CD45
discriminated EPCs from hematopoietic progenitors and
CD34 antigen distinguishes EPCs from circulating mature
endothelial cells. Additional cell types have been labeled as
EPCs and include early outgrowth cells, circulating angio-
genic cells that express Tie-2, and late outgrowth endothelial
progenitors or endothelial colony-forming cells (ECFCs) [42].
Different EPC subtypes can contribute to vascular develop-
ment and/or reconstitution to varying degrees. ECFCs, for
example, have a high rate of proliferation and can integrate
into damaged tissues in some animal studies of hind-limb
ischemia when early passage cells are used, whereas circu-
lating angiogenic cells are monocyte-derived cells that are
isolated from peripheral blood and are short lived, can home
to damaged tissues, and induce paracrine healing without
tissue integration. The recruitment of EPCs to damaged tis-
sues is facilitated by the elaboration of cytokines and other
signals after hypoxic injury, inﬂammation-induced injury,
radiation injury, or other modes of tissue damage. We
recently demonstrated that endothelial cells produced
increased levels of stromal cellederived factor (SDF)-1a after
lipopolysaccharide (LPS)-induced injury compared with
hypoxic or radiation-associated injury. The migration of
ECFCs, likewise, was mediated via distinct mechanisms with
increased expression of E-selectin ligands on ECFCs induced
by SDF-1a binding to CXCR4 after LPS-induced injury of
endothelial cells [43]. The extent to which speciﬁc angio-
genic cells or EPCs are mobilized into the peripheral circu-
lation may provide a useful prognostic biomarker, with
speciﬁc subsets of circulating CD34-positive angiogenic cells
correlating with cardiovascular risk and the number of ECFCs
correlating with Framingham risk scores [44,45].
ECFCs and circulating angiogenic cells can be readily
expanded from UCB and peripheral blood, whereas angio-
genic CD34-selected cells are more readily isolated from BM.
Moreover, UCB-derived EPCs have been shown to engraft
better after injection into ischemic tissues in experimental
animal models compared with adult-derived EPCs [46].
In addition to facilitating rapid repair of ischemic injury
in animal models, EPC-like cells can promote vascular
re-endothelialization of injured arteries, as reported in 1
preclinical study involving arterial injury in mice [47]. UCB-
derived EPCs have also been tested in the setting of
enhanced efﬁcacy of islet transplantation in a mouse model
of diabetes [48] (Figure 1).
EPC-like cells and angiogenic cells are often impaired in
patients with vascular disease, such as coronary artery dis-
ease, and in patients with diabetes, and strategies to augment
the function of these cells have been addressed by several
groups, building on insight regarding key mechanisms of ac-
tion. We recently reported on the importance of T-cell acute
lymphocytic leukemia protein-1 (TAL1) as a central tran-
scription factor that regulates a complex gene network
implicated in migration, adhesion, and tubule-forming func-
tions of ECFC [49]. Moreover, TAL1 colocalizes with enzymes
such as p300 (a histone acetylase) and various histone
deacetylases anddemethylases, underscoring the importance
of epigenetic histone modiﬁcation in the control of gene
expression networks in ECFCs. Low-dose histone deacetylase
(HDAC) inhibitorswere shown to augment the vascular repair
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vascular ischemia inmice. Others have also demonstrated the
relevance of epigenetic histone and DNA modiﬁers in the
control of EPC-like vascular repair function in animal models
and this has been recently reviewed by Fraineau et al. [50].
Inhibition of apoptotic pathways such as PI3K/Akt using
nicotine [51] andGSK-3B inhibitors also appearpromising as a
means of ex vivo priming of EPC-like cells before cell-based
vascular therapy [47].
Fucosylation is another potential mechanism relevant in
the promotion of EPC function. Overexpression of fucosyl-
transferase in EPCs enhance EPC homing function and
neovascularization in a mouse model of hind-limb ischemia
via E- and P-selectin expression improvement [52]. As
well, angiotensin converting enzyme 2 priming and over-
expression, by lentivirus transduction, improved UCB-derived
EPC migration and tube formation through upregulation of
endothelial nitric oxide synthase (eNOS) and Nox pathways
[53]. An ongoing multicenter clinical trial of autologous use of
early outgrowth EPCs transfected with eNOS continues to
enroll patients (NCT00936819 Clinicaltrials.gov identiﬁer).
Development of culture methods for manufacturing
certain EPC populations remains a challenge and upscaling
cell manufacturing and production methods remains a bar-
rier for EPC-based clinical translation. Moon et al. proposed a
xeno-free autologous culture system based on the use of
UCB-derived serum extracts combined with UCB-derived
collagen to coat plastic culture plates. UCB-derived EPCs
cultured in this culture system promote limb salvage in a
mouse model of hind-limb ischemia, suggesting that UCB
represents a source of biomaterials [54]. Other developments
are expected soon, such as serum-free media and the
development of reagents suitable for human use and potency
assays to assess cell product activity.
OTHER UCB-DERIVED CELLS WITH REGENERATIVE
CAPABILITIES
Additional nonhematopoietic stem cell populations con-
tained in UCB include unrestricted somatic stem cells
(USSCs) [55]. In culture, USSCs exhibit similar morphology to
UCB-derived MSCs although USSCs can be distinguished by
greater DLK1 expression and reduced capacity for adipocyte
differentiation [56]. Our understanding of potential devel-
opmental hierarchies of USSCs and MSCs derived from UCB
continues to be reﬁned and may shape future clinical appli-
cations in regenerative therapy.
Another MSC-like cell that can be isolated from UCB in-
cludes progenitors expressing high levels of aldehyde dehy-
drogenase. Aldehyde dehydrogenaseepositive cells have an
important regenerative capability in animal models of
ischemic disease [57], myocardial infarction [58], and islet
regeneration [59]. Additional work is needed before clinical
trials can be envisioned.
Very small embryonic-like stem cells (VSELs) have also
been described in UCB as pluripotent stem cells with sig-
niﬁcant regenerative potential. It is likely that VSELs are
retained in the discarded red cell fraction after
centrifugation-based methods of red cell depletion of UCB
units. Moreover, pluripotent genes including Oct-4, Nanog,
and Tert are expressed at high levels in VSELs [60]. Isolation
of VSELs by UCB processing may offer great potential for
regenerative therapy.
The use of induced pluripotent stem cells (iPSCs) remains
an interesting avenue for future research. Wang et al.
generated iPSCs from UCB mononuclear cells using alentiviral-mediated gene transfer [61]. The newly reprog-
rammed cells express speciﬁc pluripotency markers (Oct4,
Sox2, KLF4) at molecular and protein levels. Moreover,
reprogrammed cells can acquire the capacity to differentiate
into all the 3 germ layers [61]. UCB-derived iPSCs were also
tested as a source of dopaminergic neurons in a preclinical
rodent model of Parkinson’s disease [62]. Beyond neural
maturation, a reduced number of undifferentiated prolifer-
ating cells occurred after iPSC transplantation. This is reas-
suring regarding the potential risk associated with iPSC
therapy regarding tumor development. To date, methods of
introducing transcription factors required for cellular
reprogramming of more mature cells within UCB involves
gene transfer methods that are not ready for clinical appli-
cation. Further optimization of nonintegrative methods to
enhance gene expression may allow this technology to
evolve towards clinical application [63,64] (Figure 1).
UCB may have additional utility in regenerative applica-
tions by using cord-derived noncellular components (serum)
or platelet gels that are being tested in an ongoing clinical
trial for treatment of diabetic foot ulcers (NCT02134132
ClinicalTrials.gov identiﬁer).TECHNICAL CONSIDERATIONS FOR NOVEL CORD
BLOODeDERIVED APPLICATIONS
Although both autologous and allogeneic cord blood units
have been used for regenerative therapy and/or immune
modulation (Table 1), more studies are needed to clarify
which source of cells is preferred for speciﬁc uses in regen-
erative therapy. Moreover, implications related to banking
cord blood in public and private settings are worth consid-
ering in the context of regenerative therapy. To optimize UCB
unit utilization in regenerative medicine, integration with
current cord blood banking establishments would be most
cost effective. Current public UCB banking efforts are focused
on HLA diversity and banking units with high cellular con-
tent that will facilitate timely hematopoietic engraftment in
recipients undergoing hematopoietic stem cell trans-
plantation (HSCT). The use of UCB in regenerative applica-
tions, however, may rely on units with distinct properties
that may not be ideal for HSCT. If speciﬁc cell types are
needed, such as MSCs or ECFCs, these cells may need to be
expanded ﬁrst and stored by banking establishments or
alternatively, cryopreserved unmanipulated units could be
requested by a cell manufacturing partner or manufactured
using cell culture facilities at transplantation centers. Some
types of cellular products are best prepared using fresh cells;
however, while other applications may be feasible using
thawed units. The selection of units for regenerative appli-
cations, however, could be limited to more common HLA
haplotypes, preserving more precious UCB units from donors
with rare HLA haplotypes for HSCT. Some applications of
UCB-derived cell-based regenerative therapy may not
require stringent HLA matching at all, such as the use of
third-party MSC-like cells [65]. Recent reports suggest third-
party ECFCs do not stimulate immune reactions and may be
similar to MSCs, indicating that the use of third-party ECFCs
may be possible [66]. This will require more study, however,
to be assured that immune rejection of cells does not occur at
signiﬁcant levels. Likewise, units that contain high total
nucleated cell counts should be reserved for HSCT applica-
tions, as the dose of cells required for regenerative therapy is
less well deﬁned. Greater understanding of speciﬁc bio-
markers that characterize UCB units that are ideal for
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these units from products that are more suitable for HSCT.
Cell manufacturing methods for the production of cord
bloodederived products, such as MSCs, ECFCs, and other cell
types, remain under active development. In particular, use of
reagents approved for human use has stimulated the devel-
opment of serum-free media, synthetic coating for plastic
culture ware, and closed culture systems in highly regulated
manufacturing facilities. Interestingly, cord blood itself rep-
resents a potential source of reagents to support the growth
of particular cell products, such as MSCs, that can be
expanded using allogeneic UCB serum. MSCs cultured in this
manner displayed higher self-renewal and enhanced osteo-
genic potential in 1 study [67]. Moreover, autologous UCB
serum supplementation also appears promising [68].
Another promising opportunity related to UCB-derivedMSCs
culture is the use of platelet lysate. Generated by repeated
freeze and thaw cycles followed by membrane disruption,
platelet lysate contains growth factors, attachment factors,
microRNA, exosomes, and cytokines [69]. In parallel, UCB
plasma has also been shown to support efﬁcient expansion of
UCB-derived EPCs [70].
Because ex vivo culture can lead to spontaneous cell
transformation and uncontrolled cellular proliferation, it is
important to evaluate the safety of expanded UCB cells
before injecting into humans. Capelli et al. have proposed
that genetic abnormalities be screened by karyotype and by
more reﬁned analysis of small genetic lesions. High resolu-
tion analysis, however, is resource intensive. Sox2 and Nanog
have recently been implicated in genetic signatures associ-
ated with malignant transformation and only nonsigniﬁcant
levels of expression of these genes are normally observed in
cultured UCB-derived MSCs [11]. Rigorous safety monitoring
in preclinical animal trials and human studies will be critical.
The use of early passage cells that have not undergone
replicative senescence and remain at low risk for malignant
transformation remains an encouraging approach.
UCB CELLS AS VEHICLE IN GENE THERAPY
The use of UCB-derived cells such as MSCs is a promising
strategy for gene therapyordrugdelivery (Figure1).Onemajor
challenge in pharmacology is overcoming the blood-brain
barrier to treat neurological disorders, including neurodegen-
erative diseases. The fact that certain cell types such as MSCs
are recruited to injured sites, such as the central nervous sys-
tem, provides an opportunity to embrace the homing and
migration function of these cells as a means of gene or drug
delivery. MSCs can be modiﬁed with most viral vectors while
preserving their in vivo potential for use in gene therapy trials
[71]. One example involved adenovirus vector-associated
brain-derived neurotrophic factor delivery in an animal
model of cerebral ischemia thatwasassociatedwith signiﬁcant
functional improvement [72]. Neuroprotective effects can also
be improved by gene-modiﬁed human MSCs expressing
placental growth factor [73] or b1-integrin [74]. MSC-based
gene therapy has also been investigated in models of immu-
nomodulation inmodelsof inﬂammationandcancer [75]. Inan
animal model of glioma, adenoviral-mediated transduction of
UCB-derived MSCs to overexpress tumor necrosis factor-
related apoptosis-inducing ligand lead to inhibition of tumor
growth [76]. Engineering of UCB-derived MSCs to secret IL-12
also demonstrate enhanced migratory capacity, inhibition of
tumor growth, and prolonged survival in mice with glioma.
Beyond brain cancer, UCB-derived MSCs have been used in
gene therapy approaches in lung cancer. Zhang et al.engineered human UCB-derived MSCs to efﬁciently deliver
secretable IL-24. IL-24-delivered by MSCs inhibited growth of
lung cancer cells by apoptosis and cycle arrest [77].
Strategies to improve hematopoietic stem cell trans-
plantationhave alsodescribedgene transfer intoUCB-derived
CD34-selected hematopoietic stem cells (HSCs). CXCR4
overexpression in UCB-derived CD34-selected cells can in-
crease SDF-1emediated homing and retention in themarrow
and accelerate engraftment after transplantation in mice.
Upscaling to human clinical trials remains hampered by po-
tential safety issues linked to the immunogenicity of viral
carriers. CXCR4 overexpression using the nonviral cationic
liposome agent IBAfect (IBA, Goettingen, Germany), however,
appears promising for improving the efﬁcacy of HSCT [78].
UCB-derived hematopoietic CD34þ cells may be useful as a
vehicle for gene therapy in human immunodeﬁciency virus
(HIV) infection. Li et al. conducted preclinical studies towards
the treatment of HIV-1einfected infants with genetically
“immunized” CD34þ cells derived from UCB using antieHIV-1
hairpin ribozyme genes [79]. UCB transplantation in HIV pa-
tients using cells from donors harboring CCR5 mutations has
also been reported as a means of preventing HIV entry and
possible cure for these patients [80]. Given the rarity of CCR5
mutation in the general population, combinedwith challenges
of ﬁnding HLA-compatible units for UCB transplantation, the
development of gene-editing tools to knockout CCR5 in UCB
units may be something to consider for the future [81].
UCB CELLS SECRETOME AS AN ESSENTIAL ACCESSORY IN
REGENERATIVE MEDICINE
Many of the chief beneﬁts of cell-based vascular repair
using MSCs and EPCs have been attributed to their paracrine
actions (Figure 1). MSCs have been used in the context of
HSCT where they have an established role in the marrow
microenvironment to support hematopoiesis through direct
cell-to-cell contact and/or production of growth factors, cy-
tokines/chemokines, adhesion molecules, extracellular ma-
trix proteins, hormones, and lipid mediators [82,83].
Successful clinical trials reveal that cotransplantation of
third-party UCB-derived MSCs accelerates hematopoietic
engraftment in patients undergoing unrelated UCB trans-
plantation [65,84]. MSCs have also been used to rescue failed
engraftment after autologous hematopoietic transplantation
and likely function by providing secreted factors to restore
hematopoietic niches [85]. Another clinical trial reported
that ex vivo coculture of MSCs and HSCs was able to enhance
HSC engraftment [86]. MSCs appear to prime HSCs by reca-
pitulating some of the physiological cues of the stem cell
niche that are missing in suspension culture and in condi-
tioned transplant recipients.
UCB-derived MSCs also have immunomodulatory prop-
erties that can function much like BM-derived MSCs to
inhibit allogeneic peripheral blood mononuclear cell pro-
liferation and modulate dendritic cellemediated T
lymphocyte proliferation [87,88]. Immune modulation is
facilitated by cell contact and soluble factors, as demon-
strated in transwell systems. Soluble factors that modulate
dendritic cell function continue to be characterized but
include CD25 (IL2-R), CD38, and CD69 expression [89].
Prostaglandin E2 could also be implicated because prosta-
glandin E2 inhibition mitigates UCB-derived MSCs medi-
ated immune modulation [90]. Natural killer cells
cytotoxicity, known to accelerate immune responses, can
also be impaired by molecules expressed by UCB-derived
MSCs, including the gamma-secretase enzymes [91].
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been studied in various models of immunodegenerative
disorders, including a neonatal rat model of hyperoxia-or
pathogen-induced (Escherichia coli) lung injury [92], and
type 2 diabetes. Indeed, a phase I/II clinical trial showed that
UCB-derived multipotent progenitors that coexpress CD45
can educate autologous peripheral blood mononuclear cells
in a closed loop system and can attenuate immunological
regulators in type 2 diabetes. Insulin sensitivity was
improved after treatment with some recovery of islet b cell
function, perhaps through balancing of Th1/Th2/Th3 cyto-
kine production [93].
Paracrine effects of MSCs in regenerative applications
have also lead to the identiﬁcation of secreted bioactive
molecules. As an example, thrombospondin-2 secreted by
human UCB-derived MSCs after administration to the syno-
vial ﬂuid in patients with osteoarthritis promoted chondro-
genic differentiation. Knockdown of thrombospondin-2
expression on MSCs, using small interfering RNA, abolished
the beneﬁcial chondrogenic effects of MSCs [94].
Secretion of growth factors (VEGF, HGF, IGF, and TGF-b)
and neutrophic factors (BDNF, b-NGF) by MSCs has been
described in the context of nervous tissue regeneration
through the activation and/or modulation of endogenous
processes like the promotion of neurogenesis and angio-
genesis. In vitro and in vivo experiments show that MSCs
conditioned media is sufﬁcient to allow the increase of
neuronal survival in various neurological conditions (Par-
kinson’s disease, spinal cord injury, ischemic stroke), and
consequently, the improvement of animal behavior [95].
Although these observations were made from BM-derived
MSCs, similar results would be expected with UCB-derived
cells, given current promising results of clinical trials using
UCB-derived MSCs. Considerable potential was also reported
for MSC-secreted factors in regenerative processes associ-
ated to cardiovascular disease [83]. The use of conditioned
media from cultured MSCs has lent further support to the
important beneﬁcial role of secreted factors, particularly in
the ﬁeld of cardiac repair but also in acute kidney injury [96].
MSCs cultured under hypoxic or anoxic conditions
demonstrate a signiﬁcant increase in the secretion of several
angiogenic cytokines compared with that under normoxic
conditions [97]. Molecular preconditioning of MSCs using
bioactive proteins, such as TNF-a, SDF-1, TGF-a, or TNF-a,
represent key signaling cues to increase production of VEGF
in the conditioned medium compared with unstimulated
MSCs [98]. Moreover, MSCs can also be engineered with
transgenes for conditional gene expression with the aim of
controlling the MSC secretome [83]. Analysis of the secre-
tome of cultured MSCs must consider the effect of serum
used for cell culture, which may contain many overlapping
components and can interfere with detection. To circumvent
this problem, MSCs can be cultured for a short time frame in
serum-free medium or medium with deﬁned serum re-
placements. Moreover, it is critical to consider that secre-
tome expression in vitro is likely very different from what
would be expected in vivo where cells can interact within
different microenvironments and manifest unique secre-
tome expression proﬁles.
Regenerative immunomodulation effects associated with
UCB-derived stem cells are not limited to MSCs. Mouse acute
lung injury, induced by lipopolysaccharide challenge, is
reduced after transplantation of UCB derived CD34þ cells.
Comparatively, decreased inﬂammation (decreasing level of
TNF-a, ICAM-1, IL-6, and iNOS mRNA levels) is associatedwith restoration of vascular integrity but is not observed
after CD34 cells or PBS injection. These results suggest UCB-
derived stem cells may have a potential role in the treatment
of sepsis [99]. Ongoing human clinical trials are actively
investigating this clinical area (NCT01849237 and
NCT02421484, ClinicalTrials.gov identiﬁers).
Beyond endothelial recovery, EPCs were also shown to
increase the production of osteogenic cells after coculture
with human osteoblasts. This appears to involve a newly
described paracrine effect related to the secretion of IL-1b
from CD34þ EPCs [100]. The paracrine effect of CD133þ
endothelial progenitors from UCB also appears to be associ-
ated with bioactive molecules contained in conditioned
medium as well as tomicrovesicles released after 24 hours of
culture. CD133þ cell-derived microvesicles express mRNAs
for several antiapoptotic and proangiopoietic factors,
including kit ligand, IGF-1, VEGF, basic ﬁbroblast growth
factor, and IL-8 [101].
CONCLUSION
In summary, enthusiasm and momentum are increasing
for the use of nonhematopoietic progenitor cells from human
UCB for regenerative and immune modulatory treatments.
MSC derived from cord blood have progressed to the point of
clinical studies and routine clinical therapy appears immi-
nent. Use of endothelial-like progenitors and other cell types
continues to accelerate towards clinical application. The
economics of cord blood banking and issues related to the
cord blood bioeconomy will be continue to be considered in
the coming years as cord blood banking efforts mature.
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